NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

HOWL

Werewolf Therapeutics Inc

Jul 01 • 04:00PM ET

1.05

Dollar change -0.04
Percentage change -3.67	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BLUE BMRN EDIT RCKT SGMO CLLS ADVM SLDB

| Held by: VTI VXF VTWO IWM IWN VTWV IWO IWC VTWG VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.64	Insider Own	26.20%	Shs Outstand	44.83M	Perf Week	-16.00%
Market Cap	47.12M	Forward P/E	-	EPS next Y	-1.72	Insider Trans	4.70%	Shs Float	33.12M	Perf Month	-13.22%
Enterprise Value	-7.91M	PEG	-	EPS next Q	-0.47	Inst Own	47.56%	Short Float	5.54%	Perf Quarter	8.00%
Income	-72.41M	P/S	41.33	EPS this Y	-6.99%	Inst Trans	-4.23%	Short Ratio	3.63	Perf Half Y	-33.96%
Sales	1.14M	P/B	0.82	EPS next Y	1.61%	ROA	-50.84%	Short Interest	1.84M	Perf YTD	-29.05%
Book/sh	1.28	P/C	0.51	EPS next 5Y	-3.68%	ROE	-82.81%	52W High	4.18 -74.88%	Perf Year	-58.17%
Cash/sh	2.05	P/FCF	-	EPS past 3/5Y	39.54% -20.76%	ROIC	-77.94%	52W Low	0.60 76.47%	Perf 3Y	-77.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-55.38%	Volatility	9.65% 10.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-6.94	EPS Y/Y TTM	-50.02%	Oper. Margin	-6511.20%	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.09	Sales Y/Y TTM	-92.95%	Profit Margin	-6335.17%	RSI (14)	42.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.09	EPS Q/Q	-3.67%	SMA20	-15.10%	Beta	0.62	Target Price	8.40
Payout	-	Debt/Eq	0.65	Sales Q/Q	-100.00%	SMA50	-4.27%	Rel Volume	0.77	Prev Close	1.09
Employees	46	LT Debt/Eq	0.62	Earnings	May 08 BMO	SMA200	-30.48%	Avg Volume	505.16K	Price	1.05
IPO	Apr 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.32% -	Trades		Volume	386,964	Change	-3.67%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Initiated	JMP Securities	Mkt Outperform	$12
Aug-24-23	Initiated	Wedbush	Outperform	$9
Jun-06-23	Resumed	Jefferies	Buy	$11 → $12
Sep-10-21	Initiated	BofA Securities	Buy	$26
May-25-21	Initiated	SVB Leerink	Outperform	$29
May-25-21	Initiated	Jefferies	Buy	$22
May-25-21	Initiated	H.C. Wainwright	Buy	$32
May-25-21	Initiated	Evercore ISI	Outperform	$23

Jun-12-25 08:00AM	Werewolf Therapeutics to Participate in the BIO International Convention (GlobeNewswire)
May-29-25 12:00PM	Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know (Zacks)
08:00AM	Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 (GlobeNewswire) -5.26%
May-13-25 08:00AM	Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
07:00AM	Loading…
May-08-25 07:00AM	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.54%
May-06-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-25 08:05AM	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire)
08:00AM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 08:00AM	Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer (GlobeNewswire) +8.37%
Mar-31-25 08:00AM	Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.61%
Mar-11-25 07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-25 08:00AM	Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-24-25 07:30AM	Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors (GlobeNewswire)
08:35AM	Loading…
Jan-14-25 08:35AM	Werewolf Therapeutics provides business update, highlights 2025 outlook (TipRanks)
Jan-13-25 08:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook (GlobeNewswire)
Nov-20-24 08:00AM	Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference (GlobeNewswire)
Nov-07-24 09:02AM	Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) -8.20%
09:00AM	Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 08:00AM	Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE Molecule for Inflammatory Diseases (GlobeNewswire) -5.02%
Oct-20-24 06:04AM	Bank of America Predicts up to ~390% Surge for These 2 Strong Buy Stocks (TipRanks)
Oct-04-24 09:00AM	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.09%
Aug-08-24 08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.19%
07:05AM	Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-25-24 07:00AM	Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (GlobeNewswire) -10.34%
Jun-01-24 09:00AM	Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors (GlobeNewswire)
May-30-24 08:00AM	Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.30%
May-23-24 05:00PM	Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting (GlobeNewswire) +5.52% -5.43%
01:53PM	Loading…
May-03-24 01:53PM	HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-24 10:05AM	Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 08:00AM	Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire) +5.75%
Apr-15-24 12:00PM	All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy (Zacks) +17.06%
Apr-05-24 04:30PM	Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting (GlobeNewswire) -9.12%
Apr-04-24 04:30PM	Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR Platform in Immunology-Based Diseases at AAI Annual Meeting (GlobeNewswire)
Mar-12-24 09:55AM	How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37% (Zacks)
Mar-07-24 02:52PM	HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:45AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 08:00AM	Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 (GlobeNewswire)
Jan-08-24 07:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook (GlobeNewswire)
Jan-04-24 04:05PM	Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors (GlobeNewswire) +20.69%
Nov-22-23 07:00AM	Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 04:25PM	Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 07:00AM	Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +47.44%
Oct-31-23 09:00AM	Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-27-23 04:58AM	Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength? (Zacks) +6.49%
Sep-27-23 09:00AM	Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +11.00%
Sep-11-23 04:05PM	Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 (GlobeNewswire)
Sep-05-23 04:05PM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 09:57AM	Nvidia upgraded, Estee Lauder downgraded: Wall Street's top analyst calls (The Fly) +26.74%
Aug-13-23 08:04AM	Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? (Simply Wall St.)
Aug-11-23 03:21PM	Werewolf Therapeutics Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Aug-10-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-30-23 06:10AM	Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$11m last week but private equity firms profited the most (Simply Wall St.) +5.90%
Jun-01-23 07:00AM	Werewolf Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +14.42%
May-11-23 08:35AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.88%
07:00AM	Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 07:00AM	Werewolf Therapeutics to Participate in May Investor Conferences (GlobeNewswire) +5.49%
Apr-19-23 10:00AM	Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE Molecule, in Cancer Immunology Research (GlobeNewswire)
Mar-23-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.24%
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-16-23 07:30AM	UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-15-23 07:30AM	Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023 (GlobeNewswire)
Feb-24-23 07:30AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330 (GlobeNewswire) -13.77%
Feb-17-23 05:08AM	Investors in Werewolf Therapeutics (NASDAQ:HOWL) have unfortunately lost 53% over the last year (Simply Wall St.)
Feb-07-23 07:00AM	Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 05:16AM	Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) top owners are private equity firms with 42% stake, while31% is held by institutions (Simply Wall St.) +22.51%
Dec-12-22 10:22AM	Is Werewolf Therapeutics (NASDAQ:HOWL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +7.26%
Nov-10-22 09:00AM	Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE Molecule, at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 04:05PM	Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-07-22 07:00AM	Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 07:00AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors (GlobeNewswire) +19.57%
Aug-15-22 06:45AM	Shareholders in Werewolf Therapeutics (NASDAQ:HOWL) are in the red if they invested a year ago (Simply Wall St.)
Aug-11-22 07:00AM	Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +14.02%
Aug-03-22 07:00AM	Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Jul-05-22 07:54AM	We Think Werewolf Therapeutics (NASDAQ:HOWL) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-06-22 04:51PM	Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +21.22%
May-10-22 07:00AM	Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +10.95%
Apr-08-22 02:29PM	JAZZ Inks Deal With Werewolf to Add Oncology Candidate (Zacks)
01:00PM	Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE Molecules at AACR 2022 Annual Meeting (GlobeNewswire)
Apr-07-22 09:25AM	Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma (Benzinga) +23.47%
08:34AM	Jazz, Werewolf sign licensing deal worth up to $1.2 billion (MarketWatch)
07:00AM	Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFN INDUKINE Molecule (PR Newswire)
Mar-24-22 07:00AM	Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-16-22 08:00AM	Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment (GlobeNewswire)
Mar-15-22 08:00AM	Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting (GlobeNewswire)
Feb-08-22 08:00AM	Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-26-22 06:53AM	Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-05-22 08:00AM	Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-14-21 04:01PM	Werewolf Therapeutics Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-01-21 08:00AM	Werewolf Therapeutics to Present Preclinical Data on INDUKINE Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.45%
Nov-10-21 07:00AM	Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update (GlobeNewswire)
Nov-08-21 08:03AM	Werewolf Therapeutics to Present at Upcoming Conferences in November 2021 (GlobeNewswire)

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	May 12 '25	Buy	0.86	320,913	275,985	6,021,969	May 14 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 14 '25	Buy	0.98	162,539	159,288	6,237,482	May 14 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 13 '25	Buy	0.98	52,974	51,915	6,074,943	May 14 06:08 PM
MPM BioVentures 2014, L.P.	10% Owner	Mar 27 '25	Sale	1.05	1,963	2,061	3,208,793	Apr 30 04:17 PM
EVNIN LUKE	Director	Mar 27 '25	Sale	1.05	2,425	2,546	4,309,860	Apr 30 04:09 PM
GADICKE ANSBERT	10% Owner	Mar 27 '25	Sale	1.05	4,386	4,605	6,718,670	Apr 30 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HOWL

Werewolf Therapeutics Inc

Upgrade your FINVIZ experience